TG02 (Double bond E) is primarily utilized in the field of medicinal chemistry and drug development. It functions as a potent inhibitor targeting specific kinases involved in cell cycle regulation and cancer progression. Its application is significant in preclinical research, where it is studied for its potential to induce apoptosis and inhibit tumor growth in various cancer models. Additionally, TG02 is explored for its synergistic effects when combined with other therapeutic agents, enhancing its efficacy in combating resistant cancer cells. Its role in modulating key signaling pathways makes it a promising candidate for developing targeted cancer therapies.